MCRB Stock Chart

Seres Therapeutics is a microbiome therapeutics platform company which engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology to treat multiply recurrent Clostridium difficile infection. The Company also develops a number of other product candidates for treatment of various diseases, including ulcerative colitis, Clostridium difficile infection, inflammatory bowel disease, etc.